AQR Capital Management LLC Sells 16,909 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

AQR Capital Management LLC reduced its stake in Inozyme Pharma, Inc. (NASDAQ:INZY) by 61.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,807 shares of the company’s stock after selling 16,909 shares during the quarter. AQR Capital Management LLC’s holdings in Inozyme Pharma were worth $48,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new stake in shares of Inozyme Pharma in the second quarter valued at about $68,000. Values First Advisors Inc. bought a new stake in Inozyme Pharma in the 2nd quarter valued at approximately $76,000. Cubist Systematic Strategies LLC acquired a new position in Inozyme Pharma during the 2nd quarter worth approximately $84,000. American Century Companies Inc. boosted its position in Inozyme Pharma by 11.0% during the 2nd quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock worth $255,000 after acquiring an additional 5,673 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Inozyme Pharma by 22.0% during the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after acquiring an additional 13,867 shares in the last quarter. 88.30% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on INZY. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Inozyme Pharma in a research report on Thursday, August 8th. Wedbush restated an “outperform” rating and issued a $15.00 price objective on shares of Inozyme Pharma in a report on Monday, September 30th. Stifel Nicolaus started coverage on Inozyme Pharma in a report on Thursday, September 12th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Jefferies Financial Group restated a “buy” rating and issued a $17.00 price target (up from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $16.14.

Inozyme Pharma Trading Up 7.6 %

Shares of NASDAQ:INZY opened at $5.54 on Friday. Inozyme Pharma, Inc. has a 52-week low of $2.69 and a 52-week high of $7.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 9.84 and a current ratio of 9.84. The company has a market capitalization of $342.68 million, a P/E ratio of -4.04 and a beta of 1.51. The company has a 50-day simple moving average of $5.24 and a 200 day simple moving average of $5.00.

Inozyme Pharma (NASDAQ:INZY) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Sell-side analysts forecast that Inozyme Pharma, Inc. will post -1.68 earnings per share for the current year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.